Amgen Acquires Dark Blue Therapeutics

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed the acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction at approximately $27.8 billion. The deal expands Amgen's inflammation and rare-disease portfolio by adding Horizon's medicines (including TEPEZZA, KRYSTEXXA and UPLIZNA) and strengthens Amgen's biologics R&D, manufacturing and global commercial capabilities.

Pfizer Acquires Global Blood Therapeutics for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer Inc. has agreed to acquire Global Blood Therapeutics, Inc. for $68.50 per share in cash, valuing the transaction at approximately $5.4 billion including debt. The acquisition brings GBT's sickle cell disease portfolio (including Oxbryta) and pipeline to Pfizer to expand its rare hematology capabilities and accelerate access to therapies for underserved SCD patient communities.

Biotage AB Acquires ATDBio

October 20, 2021

Biotechnology

Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.

Amgen Inc. Acquires Rodeo Therapeutics

March 30, 2021

Biotechnology

Amgen Inc. has agreed to acquire privately held Rodeo Therapeutics, a Seattle-based biopharmaceutical company focused on small-molecule modulators of prostaglandin biology, including a lead 15-PGDH program. The deal includes a $55 million upfront cash payment plus up to $666 million in potential contingent milestone payments and is intended to expand Amgen's inflammation and tissue-regeneration capabilities.

Mirum Pharmaceuticals Acquires Bluejay Therapeutics

January 26, 2026

Pharmaceuticals

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.